top of page

FOUNDING TEAM

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.

FOUNDING TEAM

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.

FOUNDING TEAM

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.

FOUNDING TEAM

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.

PD Dr. Andrea Chicca

Project leader/senior scientist at UniBern.

2 years in pharma industry.

8 years of research activity on the ECS

Prof. Dr. Jürg Gertsch

Full Professor at UniBern.
Collaboration with pharma industry.
10+ years of research activity on the ECS.

Search

November 2018 // Company

andreachicca797
Nov 1, 2018
1 min read

Synendos Therapeutics was selected for the initial Innosuisse coaching programme and awarded with CHF 5’000. The coaching programme supports the initial growth of the business idea and helps developing its feasibility and marketability.

https://www.innosuisse.ch/inno/en/home/start-and-grow-your-business/start-up-coaching.html

Recent Posts

January 2024 // Company & Communication

Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510. Synendos transitions to a...

October 2022 // Company

Synendos Therapeutics has been awarded with the Innosuisse Certificate Synendos has been awarded the Innosuisse certificate by Innosuisse...

September 2022 // Company & Communication

Synendos Therapeutics is ranked TOP 100 Swiss Startups 2022 We are honored to be listed for the second year in a row as one of the TOP...

bottom of page